Burden of chemotherapy-induced myelosuppression (CIM) in Chinese patients with extensive-stage small cell lung cancer (ES-SCLC): A retrospective real-world study

作者：Kailun Fei, Wenjing Yang, Jianchun Duan, Jiachen Xu, Jie Zhao, Jie Wang, Zhijie Wang · 发表于：Chinese Medical Journal - Pulmonary and Critical Care Medicine · 年份：2025 · DOI：10.1016/j.pccm.2025.08.004 · 被引用次数：2 · 研究领域：Lung Cancer Research Studies、Neutropenia and Cancer Infections、Multiple Myeloma Research and Treatments

The disease burden, treatment patterns, and financial costs associated with chemotherapy-induced myelosuppression (CIM) in Chinese patients with extensive-stage small cell lung cancer (ES-SCLC) remain poorly characterized, particularly in terms of real-world evidence derived from large populations. This study aimed to describe the incidence, treatment patterns, costs, and healthcare resource utilization (HCRU) in Chinese patients with ES-SCLC who develop CIM. Adults diagnosed with ES-SCLC who started etoposide–platinum (EP) chemotherapy for the first time between January 1, 2018 and December 31, 2022 were retrospectively identified in the Chinese National Cancer Information Database. Baseline demographic and clinical data were collected. Information on CIM-related events, treatment, costs, and HCRU during EP chemotherapy and during follow-up was assessed. Costs and HCRU were compared among patients with grade 3–4 CIM, grade 1–2 CIM, and no CIM using the Kruskal–Wallis test. In total, 7505 patients with ES-SCLC (mean age 61.2 years; 17.7 % [1332/7505] female; body mass index 23.2±3.3 kg/m 2 ) were enrolled. After initiation of EP-based chemotherapy, 6901 patients (92.0 %) experienced at least one CIM-related event. At least one grade 3–4 CIM event occurred in 1883 patients (25.1 %) and consisted of single-lineage (neutropenia [ n =609, 8.1 %], thrombocytopenia [ n =85, 1.1 %], anemia [ n =797, 10.6 %]), two-lineage ( n =318, 4.2 %), and three-lineage ( n =74, 1.0 %) events. Pa...